Get 40% Off
👀 👁 🧿 All eyes on Biogen, up +4,56% after posting earnings. Our AI picked it in March 2024.
Which stocks will surge next?
Unlock AI-picked Stocks

Medicare to expand coverage of Genomic Health's prostate cancer test October 9

Published 08/24/2017, 08:36 AM
Updated 08/24/2017, 08:36 AM
© Reuters.  Medicare to expand coverage of Genomic Health's prostate cancer test October 9
  • Genomic Health (NASDAQ:GHDX) announces that Medicare will start covering the use of its Oncotype DX Genomic Prostate Score (GPS) test in qualified patients with favorable intermediate-risk prostate cancer on October 9. Medicare has covered the use of the test in low-risk patients since 2015.
  • The company says the new coverage will expand access by 20K men, adding to the 50K low-risk patients already covered.
  • Now read: China Cord Blood FQ1 top line up 30%, earnings up 340%, cash flow up 73%; shares ahead 15% premarket


Original article

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.